Open AccessPB1986: ADDITION OF CARFILZOMIB AS A THIRD AGENT IN LENALIDOMIDE‐REFRACTORY MULTIPLE MYELOMA: SWITCHING FROM DOUBLET TO TRIPLET
Author(s) -
Cerchione C.,
Nappi D.,
Pareto A. E.,
Ronconi S.,
Cangini D.,
Ceccolini M.,
Musuraca G.,
Catalano L.,
Martinelli G.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000850780.44378.43
Subject(s) - lenalidomide , carfilzomib , medicine , regimen , multiple myeloma , dexamethasone , refractory (planetary science) , bortezomib , oncology , salvage therapy , surgery , chemotherapy , biology , astrobiology